Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Advisorshares Psychedelics ETF (NY: PSIL )

1.700 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.700
Bid (Size) 1.670 (2)
Ask (Size) 1.780 (1)
Prev. Close 1.700
Today's Range 1.700 - 1.700
52wk Range 1.650 - 4.350
Shares Outstanding 36,250
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga

Performance

YTD
-10.99%
-10.99%
1 Month
-3.13%
-3.13%
3 Month
-16.67%
-16.67%
6 Month
-26.41%
-26.41%
1 Year
-41.58%
-41.58%

More News

Read More
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Via Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
Via Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Via Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Via Benzinga
ETFs Outperforming The S&P 500, On Average
Via Talk Markets
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Via Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
Via Benzinga
Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More
Via Benzinga
"Multi-Bagger" Portfolio Down 13% In March; Still Up Almost 6% YTD
Via Talk Markets
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
Via Benzinga
Our Aggressive ETF Portfolio Is Outperforming The S&P 500 By A 2-To-1 Margin
Via Talk Markets
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Via Benzinga
An Aggressive ETF Portfolio For 2023: An Update
Via Talk Markets
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Via Benzinga
An Update On The Performance Of The 7 Largest Psychedelic Stocks
Via Talk Markets
The "Multi-Bagger" Portfolio: An Update
Via Talk Markets
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Via Benzinga
Largest Psychedelic Stocks Down 13% Last Week; Down 20% YTD
Via Talk Markets
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Via Benzinga
An Aggressive ETF Portfolio For 2023
Via Talk Markets
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Via Benzinga
"Rags-To-Riches" Portfolio Outpacing S&P 500 By 2-To-1 Margin
Via Talk Markets
"Multi-Bagger" Portfolio Outperforming "Rags-To-Riches" Portfolio By 2-To-1 Margin YTD
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.